Axovant Sciences Ltd - Company & Market Research Reports

Axovant Sciences is a biopharmaceutical company that focuses on developing and commercializing novel therapeutics for the treatment of dementia in the United States and Europe. Its best known product, intepirdine, is a selective 5-HT6 receptor antagonist. It is currently in Phase III clinical trial for the treatment of Alzheimer's disease and in Phase II clinical trial for treating dementia. The company was formerly known as Roivant Neurosciences. Founded in 2014, it is based in Hamilton, Bermuda.


Global Alzheimer's Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2015 to 2022 - Product Thumbnail Image

Global Alzheimer's Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2015 to 2022

  • Report
From
Global Alzheimer's Therapeutics Market Analysis 2016 - Forecast to 2022 - Product Thumbnail Image

Global Alzheimer's Therapeutics Market Analysis 2016 - Forecast to 2022

  • Report
  • 138 Pages
From
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets - Product Thumbnail Image

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

  • Report
  • 144 Pages
From
Global Alzheimer’s Drug Market: Trends, Opportunities and Forecasts (2015-2020) (By Type - Imaging, Therapeutics, Diagnostics, Biomarkers; By Age: <65 years, >65 years age; By Region; Global Dementia Market) - Product Thumbnail Image

Global Alzheimer’s Drug Market: Trends, Opportunities and Forecasts (2015-2020) (By Type - Imaging, Therapeutics, Diagnostics, Biomarkers; By Age: <65 years, >65 years age; By Region; Global Dementia Market)

  • Report
  • 106 Pages
From
Alzheimer's Disease - Pipeline Review, H1 2018 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H1 2018

  • Report
  • 1203 Pages
From
Dementia - Pipeline Review, H1 2018 - Product Thumbnail Image

Dementia - Pipeline Review, H1 2018

  • Report
  • 260 Pages
From
Parkinson's Disease - Pipeline Review, H2 2017 - Product Thumbnail Image

Parkinson's Disease - Pipeline Review, H2 2017

  • Report
  • 831 Pages
From
Lewy body Dementia - Pipeline Review, H2 2016 - Product Thumbnail Image

Lewy body Dementia - Pipeline Review, H2 2016

  • Report
  • 48 Pages
From
Lewy body Dementia - Pipeline Review, H1 2016 - Product Thumbnail Image

Lewy body Dementia - Pipeline Review, H1 2016

  • Report
  • 40 Pages
From
Lewy body Dementia - Pipeline Review, H2 2015 - Product Thumbnail Image

Lewy body Dementia - Pipeline Review, H2 2015

  • Report
  • 46 Pages
From
Cognitive Impairment Disorders Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Cognitive Impairment Disorders Drug Development Pipeline Review, 2018

  • Report
  • 376 Pages
From
Neurodegenerative Disorders Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Neurodegenerative Disorders Drug Development Pipeline Review, 2017

  • Report
  • 797 Pages
From
Reversible Anticholinesterases -Pipeline Insight, 2018 - Product Thumbnail Image

Reversible Anticholinesterases -Pipeline Insight, 2018

  • Drug Pipelines
  • 90 Pages
From
Business Update Call - Axovant Sciences Ltd., - Earnings Transcript - Product Thumbnail Image

Business Update Call - Axovant Sciences Ltd., - Earnings Transcript

  • Earnings Transcript
Jefferies Global Healthcare Conference - Axovant Sciences Ltd., - Earnings Transcript - Product Thumbnail Image

Jefferies Global Healthcare Conference - Axovant Sciences Ltd., - Earnings Transcript

  • Earnings Transcript
Executive Update Call - Axovant Sciences Ltd., - Earnings Transcript - Product Thumbnail Image

Executive Update Call - Axovant Sciences Ltd., - Earnings Transcript

  • Earnings Transcript
Business Update Call - Axovant Sciences Ltd. - Earnings Transcript - Product Thumbnail Image

Business Update Call - Axovant Sciences Ltd. - Earnings Transcript

  • Earnings Transcript
J.P. Morgan Health Care Conference - Axovant Sciences Ltd., - Earnings Transcript - Product Thumbnail Image

J.P. Morgan Health Care Conference - Axovant Sciences Ltd., - Earnings Transcript

  • Earnings Transcript
Intepirdine Phase 3 Clinical Trial Results Call - Axovant Sciences Ltd. - Earnings Transcript - Product Thumbnail Image

Intepirdine Phase 3 Clinical Trial Results Call - Axovant Sciences Ltd. - Earnings Transcript

  • Earnings Transcript
Robert W. Baird Global Health Care Conference - Axovant Sciences Ltd., - Earnings Transcript - Product Thumbnail Image

Robert W. Baird Global Health Care Conference - Axovant Sciences Ltd., - Earnings Transcript

  • Earnings Transcript
Loading Indicator
adroll